Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fed Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg

NCT00649506
View directory record Official record
Conditions
Healthy
Interventions
Nitrofurantoin Macrocrystals 100 mg Capsules, Macrodantin® 100 mg Capsules
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
View directory record Official record
Conditions
Schizophrenia
Interventions
10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addition to Infant Formula of 2-fucosyllactose (2-FL)

NCT03109223
View directory record Official record
Conditions
Growth of Infants
Interventions
sole source nutrition
Other
Lead sponsor
PBM Nutritionals
Industry
Eligibility
4 Days to 36 Days
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Evansville, Indiana • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Prasugrel in Healthy Participants

NCT01648790
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Prasugrel ODT1 - Tablet, Prasugrel ODT2 - Tablet, Prasugrel ODT2 - Suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

NCT02935946
View directory record Official record
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

NCT01380431
View directory record Official record
Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
Lisinopril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

NCT02888054
View directory record Official record
Conditions
Healthy
Interventions
lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT04243083
View directory record Official record
Conditions
Healthy
Interventions
TLL018 tablet, placebo
Drug
Lead sponsor
TLL Pharmaceutical, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers

NCT01440166
View directory record Official record
Conditions
Healthy
Interventions
Drug, Placebo
Drug · Other
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 17, 2026, 7:14 AM EDT
Terminated Phase 1 Interventional

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

NCT07431398
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Pociredir
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Riverdale, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

NCT06698575
View directory record Official record
Conditions
Recurrent Genital Herpes Simplex Type 2
Interventions
ABI-1179, ABI-1179 Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Levetiracetam 1000 mg Under Non-Fasting Conditions

NCT00859430
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam, Keppra®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Results available

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3326595, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

NCT01530542
View directory record Official record
Conditions
Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders
Interventions
oxycodone hydrochloride, marketed oxycodone hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

NCT00775359
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate 160 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of E2086 in Healthy Adult Participants

NCT06481488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 17, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Kidney Axis in Enteric Hyperoxaluria

NCT05124886
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
Moderately High Oxalate (MOx) Diet
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

NCT05076877
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Midazolam, Rosuvastatin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions

NCT00601575
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
25 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 7:14 AM EDT
Suspended Phase 1 Interventional

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

NCT04996030
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
SY-2101, Arsenic Trioxide
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 17, 2026, 7:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions

NCT01659892
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 7:14 AM EDT